
## Ho Tsoi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8156793/publications.pdf Version: 2024-02-01



Ho Teo

#	Article	IF	CITATIONS
1	BQ323636.1, a Novel Splice Variant to <i>NCOR</i> 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research, 2018, 24, 3681-3691.	7.0	23
2	Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer. Cancers, 2021, 13, 1511.	3.7	22
3	Phosphorylation independent elF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer. Oncogene, 2020, 39, 3206-3217.	5.9	18
4	Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer. Biomolecules, 2022, 12, 72.	4.0	18
5	Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer. Cancers, 2022, 14, 1251.	3.7	11
6	KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer. Clinical and Translational Medicine, 2021, 11, e554.	4.0	10
7	A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2. Cancers, 2020, 12, 533.	3.7	7
8	Repurposing hyperpolarizationâ€activated cyclic nucleotideâ€gated channels as a novel therapy for breast cancer. Clinical and Translational Medicine, 2021, 11, e578.	4.0	7
9	Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life, 2022, 12, 93.	2.4	4